Literature DB >> 20156000

Reducing patient harm with the use of fentanyl transdermal system.

Matthew Grissinger1, Michael J Gaunt.   

Abstract

Fentanyl transdermal system is indicated for the management of persistent, moderate-to-severe chronic pain that requires continuous opioid administration for an extended period of time and cannot be managed by other means such as nonsteroidal analgesics, opioid combination products, or immediate-release opioids. The Institute for Safe Medication Practices and other patient safety advocates have long been concerned that transdermal fentanyl is often prescribed, dispensed, and administered without proper consideration of patient selection criteria, starting-dose recommendations, contraindications, dose adjustment recommendations, and safe administration procedures. This article will highlight errors that may arise during the use of fentanyl patches and provide risk-reduction recommendations for consultant pharmacists to address the potential for error and patient harm.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20156000     DOI: 10.4140/tcp.n.2009.864

Source DB:  PubMed          Journal:  Consult Pharm        ISSN: 0888-5109


  2 in total

1.  Unmet Needs for Transdermal Patch Management in Electronic Medication Administration Records: An Analysis of Data from 66 Aged Care Facilities.

Authors:  Magdalena Z Raban; Melissa T Baysari; Mikaela L Jorgensen; Amina Tariq; Andrew Georgiou; Johanna I Westbrook
Journal:  Appl Clin Inform       Date:  2020-12-09       Impact factor: 2.342

2.  Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system.

Authors:  Henrik Lövborg; Mikael Holmlund; Staffan Hägg
Journal:  BMC Pharmacol Toxicol       Date:  2014-06-09       Impact factor: 2.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.